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ABSTRACT
Background and Aims: Elevated circulating concentrations of the hormone 
gastrin contribute to the development of gastric adenocarcinoma and types-1 and 2 
gastric neuroendocrine tumors (NETs). MicroRNAs (miRNAs) are small non-coding 
RNAs that post-transcriptionally regulate proteins which in turn influence various 
biological processes. We hypothesised that gastrin induces the expression of specific 
gastric miRNAs within CCK2 receptor (CCK2R) expressing cells and that these mediate 
functionally important actions of gastrin.
Results: Gastrin increased miR-222 expression in AGSGR cells, with maximum 
changes observed at 10 nM G17 for 24 h. Signalling occurred via CCK2R and the PKC 
and PI3K pathways. miR-222 expression was increased in the serum and gastric 
corpus mucosa of hypergastrinemic INS-GAS mice and hypergastrinemic patients 
with autoimmune atrophic gastritis and type 1 gastric NETs; it decreased in patients 
following treatment with the CCK2R antagonist netazepide (YF476). Gastrin-
induced miR-222 overexpression resulted in reduced expression and cytoplasmic 
mislocalisation of p27kip1, which in turn caused actin remodelling and increased 
migration in AGSGR cells. 
Materials and Methods: miRNA PCR arrays were used to identify changes in 
miRNA expression following G17 treatment of human gastric adenocarcinoma cells 
stably transfected with CCK2R (AGSGR). miR-222 was further investigated using primer 
assays and samples from hypergastrinemic mice and humans. Chemically synthesised 
mimics and inhibitors were used to assess cellular phenotypical changes associated 
with miR-222 dysregulation. 
Conclusions: These data indicate a novel mechanism contributing to gastrin-
associated gastric tumor development. miR-222 may also be a promising biomarker 
for monitoring gastrin induced premalignant changes in the stomach.
INTRODUCTION
Elevated circulating concentrations of the gastric 
antral hormone gastrin are found in patients who 
are hypochlorhydric as a result of atrophic gastritis. 
Autoimmune atrophic gastritis predisposes to the 
development of type 1 gastric neuroendocrine (carcinoid) 
tumors (NETs) [1, 2]. Hypergastrinemia is crucial for the 
development of these tumors, as surgical antrectomy to 
remove the source of hypergastrinemia [3] or treatment 
with gastrin/CCK2 receptor antagonist drugs can reverse 
tumor development [4, 5]. Helicobacter pylori induced 
atrophic gastritis also results in hypergastrinemia 
and this is thought to act as a co-factor during gastric 
adenocarcinoma development. This is supported by 
animal studies which have demonstrated accelerated 
H. pylori induced gastric carcinogenesis in transgenic 
hypergastrinemic INS-GAS mice [6, 7].
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Gastrin contributes to gastric tumor development via 
several cellular mechanisms. These are in addition to its 
well established role in regulating gastric acid secretion 
and include alterations in cell proliferation, apoptosis, 
migration, differentiation and angiogenesis (reviewed 
in [8–10]). Moreover several proteins including Reg 
[11], MMP-7 [12], MMP-1 [13] and members of the 
urokinase plasminogen activator family of proteins [14] 
show increased expression in the stomach or serum of 
patients with hypergastrinemia. Many of these proteins 
are thought to contribute to gastric tumorigenesis by 
altering key functions including cell migration and 
differentiation. Some may also have utility as biomarkers 
of tumor development. Gastrin exerts its effects in the 
stomach predominantly as a result of binding to the CCK2 
receptor (CCK2R) on enterochromaffin-like (ECL) cells. 
Downstream signalling occurs via a number of pathways, 
including protein kinase C (PKC), MAP kinase (MAPK), 
and phosphatidylinositol (PI) 3-kinase (PI3K) [8, 9].
MicroRNAs (miRNAs) are a class of endogenous 
non-protein coding short RNAs that post-transcriptionally 
regulate approximately 30% of the human genome [15, 16]. 
They inhibit the translation, increase cleavage or induce 
the degradation of target mRNAs depending upon 
complementary RNA-RNA binding [17]. As miRNAs 
control a large proportion of the genome, their expression 
patterns are tissue-specific and dysregulation has been 
observed in many malignancies [18], suggesting the 
potential for miRNAs to be biomarkers of cancer 
diagnosis, prognosis and response to therapies. One 
gene can be regulated by many miRNAs and likewise 
one miRNA can regulate several genes, including tumor 
suppressor genes and oncogenes. This adds an additional 
layer of functional complexity, as miRNAs can act 
as both ‘oncomiRs’ to promote tumor development 
or ‘anti-oncomiRs’ to suppress tumor development, 
depending upon their tissue expression [19]. Moreover, 
> 50% miRNA genes are located within fragile sites and 
genomic regions associated with deletion, translocation 
and amplification in cancers, further indicating their 
significance during carcinogenesis [20].
We hypothesised that gastrin may exert some of 
its pro-tumorigenic effects in the stomach by altering the 
expression of specific microRNAs, which in turn alter 
the expression of downstream proteins regulating key 
cellular processes involved in gastric tumor progression. 
We have therefore investigated which miRNAs showed 
altered expression following G17 treatment of a CCK2 
receptor expressing gastric epithelial cell line. One of the 
upregulated miRNAs, miR-222, was further investigated 
using samples obtained from hypergastrinemic mice 
and humans and upstream and downstream signalling 
pathways were defined in AGSGR cells using various 
inhibitor compounds and siRNA approaches.
RESULTS
Gastrin induces miR-222 expression in AGSGR 
cells
miScript miRNA PCR Arrays were used to identify 
differentially expressed miRNAs between AGSGR cells 
treated with and without 10 nM G17 for 24 h. Three 
miRNAs showed increased expression and three miRNAs 
showed decreased expression beyond the 2-fold threshold 
(Figure 1A). However, only miR-376c and miR-222 
proved significant with fold changes of 5.2 (P < 0.01) and 
2.3 (P < 0.0001) respectively. 
Further validation was performed to confirm these 
differences. As miR-376c was of relatively low abundance 
in both the control and gastrin-treated cells (Figure 1B) 
and was also below the threshold for detection by qPCR in 
this cell line, miR-222 was chosen for further investigation. 
In parental AGS cells (not stably transfected with the 
CCK2R), gastrin treatment had no significant effect 
on miR-222 expression at concentrations of 0–100 nM 
for 2–48 h. However in AGSGR cells which express the 
CCK2R, miR-222 expression increased dose and time 
dependently following gastrin treatment and was maximal 
after administering 10 nM G17 for 24 h (Figure 1C and 1D). 
Activation of the CCK2 receptor by gastrin leads 
to increased miR-222 expression via the PKC 
and PI3K pathways in AGSGR cells
In order to investigate the signalling mechanisms 
downstream of CCK2R that were responsible for the 
observed increase in miR-222 expression, we used known 
inhibitors of these pathways. AGSGR cells were pre-
treated with the following signalling pathway inhibitors: 
Ro-32-0432 (PKC inhibitor), LY294002 (PI3K inhibitor), 
PD98059 (inhibitor of MAPK activation) and netazepide 
(YF476) or YM022 (both CCK2R antagonists) prior 
to treating the cells for 24 h with 10 nM G17. miR-222 
expression was evaluated using qPCR primer assays. 
As miRNAs are regulated by many mRNAs and vice 
versa, miRNAs may be involved in multiple signalling 
pathways. Small nuclear RNAs, such as the housekeeping 
gene RNU62 used for normalisation, may therefore also 
be regulated by the particular pathways investigated. 
Therefore, an exogenous spike in control (C.elegans 
miR-39) was used for normalisation. 
Gastrin-induced miR-222 overexpression was almost 
fully reversed when AGSGR cells were pre-treated with Ro-
32-0432 (1 µM), LY294002 (20 µM), YM022 (100 nM) 
and netazepide (100 nM) suggesting that miR-222 
expression is increased via activation of the CCK2 
receptor and subsequent PKC and PI3K pathways. 
However, there was only a partial reversal caused by the 
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inhibitor of MAPK activation, indicating that this is not 
the major pathway for miR-222 expression (Figure 1E). 
Further investigation of downstream signalling was 
performed by pre-treating AGSGR cells with and without 
PKC and PI3K inhibitors followed by activation of 
PKC via PMA 100 nM for 24 h. The activation of PKC 
stimulated a significant increase in miR-222 expression 
which was also significantly, but not completely reversed 
by pre-treatment with the PI3K inhibitor. These data 
indicate that gastrin-CCK2 receptor activation increases 
miR-222 expression via both the PKC and PI3K pathways 
in AGSGR cells (Figure 1F). 
miR-222 expression increases with age in 
hypergastrinemic INS-GAS mice 
As previously reported, miRNAs are highly stable 
in both blood and tissues [24]. miR-222 expression was 
therefore assessed in FVB/N and transgenic INS-GAS 
mice on the same genetic background. Mice were culled 
at 12 and 30 weeks of age (n = 10 per group) and gastric 
corpus mucosal scrapings and serum were used for primer 
assays. miR-222 expression was significantly increased 
in both the gastric mucosal scrapings and serum of 30 
week old INS-GAS mice compared with age-matched 
FVB/N wild-type. There was also a statistically significant 
difference between 12 week and 30 week old INS-GAS 
mice in the serum (Figure 2A and 2B). 
miR-222 expression is increased in the 
serum and gastric corpus of patients 
with hypergastrinemia and type 1 gastric 
neuroendocrine tumors, and is significantly 
reduced by netazepide treatment
We also assessed miR-222 expression in both 
gastric corpus biopsies and serum samples from patients 
with autoimmune atrophic gastritis, hypergastrinemia and 
type 1 gastric NETs who had been enrolled on a phase-2 
clinical trial to assess the short and long term effects of the 
CCK2R antagonist netazepide[4]. In addition to the initial 
12 week trial, the results of which have been reported, 
patients were treated for an additional 12 months and 
showed ongoing histological and biochemical evidence of 
tumor regression (manuscript in preparation).
There was a significant but small increase in 
miR-222 expression in the gastric corpus biopsies of 
hypergastrinemic patients before taking netazepide 
relative to normogastrinemic controls, which significantly 
decreased whilst patients were taking 50mg netazepide 
daily and returned to baseline after cessation of 
treatment, in both the short-term (12-week treatment with 
12-week follow-up) and longer-term (12-month treatment) 
regimens (Figure 2C and 2E). 
miR-222 expression was also significantly increased 
in the serum of the same hypergastrinemic patients with 
a 5.7-fold increase in the short-term study and a 5-fold 
increase in the longer study, when compared to healthy 
controls. Similarly, whilst patients were taking netazepide, 
serum miR-222 expression significantly decreased and 
returned towards baseline after cessation of treatment 
(Figure 2D and 2F). 
miR-222 overexpression increases migration and 
the extension of long processes in AGSGR cells 
Gastrin has previously been shown to increase 
the migration of AGSGR cells dose dependently after 8 h 
treatment with concentrations of 30 pM to 3 nM G17 
[22]. Incubation of AGSGR cells with 10 nM G17 for 
8 h significantly stimulated cell migration in scratch 
wound assays (Figure 3A) when compared to untreated 
AGSGR cells. Chemically synthesised miR-222 mimics 
at concentrations 10–100 nM also significantly increased 
AGSGR cell migration dose dependently (Figure 3C). By 
contrast, chemically-synthesised miR-222 inhibitors 
significantly reversed 10 nM G17 induced AGSGR cell 
migration at concentrations 50–100 nM and completely 
reversed gastrin-stimulated (10 nM) migration at 
concentration 500 nM (Figure 3E).
Incubation of AGSGR cells with 1nM G17 has also 
previously been shown to induce cell scattering and the 
extension of long processes which were maximal after 6 h 
treatment [23]. Similar responses were observed in AGSGR 
cells treated with 10nM G17 for 6 h (Figure 3B), with 
visible morphological changes observed with the extension 
of long processes (arrows). Chemically synthesised 
miR-222 mimics dose dependently increased the extension 
of long processes in AGSGR cells and this was significant 
at concentrations > 10 nM (Figure 3D). Chemically 
synthesised miR-222 inhibitors dose dependently reversed 
the extension of long processes induced by 10 nM G17 in 
AGSGR cells, which was significant after treatment with 
concentrations > 50 nM (Figure 3F). 
Gastrin-induced miR-222 overexpression 
decreases the expression of p27 in vitro and  
in vivo, via the PKC and PI3K pathways
In AGSGR cells, qPCR primer assays showed that p27 
mRNA expression decreased in dose (Figure 4A) and time 
(Figure 4B) dependent manners following G17 treatment, 
which was maximal after 10 nM G17 for 24 h. Western 
blots indicated that AGSGR cells incubated with G17 also 
showed dose (Figure 4C) and time (Figure 4D) dependent 
decreases in p27 protein expression. This was again 
significant after treating cells with 10 nM G17 for 24 h. 
Immunofluorescence visualisation (Figure 4E) 
showed a dose dependent increase in cytoplasmic 
abundance of p27 that was significant at a concentration 
1 nM and maximal at concentration 10 nM G17 for 24 h. 
A reciprocal dose dependent decrease in nuclear p27 
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Figure 1: In AGSGR cells treated with 10nM G17 compared with untreated controls, miScript miRNA PCR arrays 
showed 3 miRNAs that increased and 3 miRNAs that decreased in expression beyond the 2-fold threshold, with only 
miR-222 and miR-376c proving significant. (A) As the abundance of miR-376c was low in both the treated and untreated samples, 
miR-222 was further investigated (B). miR-222 expression increased dose and time dependently in AGSGR cells and was maximal following 
treatment with 10nM G17 for 24h in serum free media. miR-222 expression did not significantly change following G17 treatment of 
untransfected AGS cells (C, D). LY294002 (20 μM), YM022 (100 nM), netazepide (100 nM) and Ro-32-0432 (1 μM) all completely 
reversed while PD98089 (20 μM) partially reversed the miR-222 overexpression caused by 10 nM G17 treatment of AGSGR cells for 24 h 
(E). Ro-32-0432 (1 μM) also completely reversed while LY294002 (20 μM) partially reversed the miR-222 overexpression induced by 
100 nM PMA treatment of the same cell line for 24 h (F). Statistical significance was determined using two-way ANOVA with Sidak post-
hoc test and P < 0.05 was considered significant. **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Oncotarget45466www.impactjournals.com/oncotarget
expression was observed after 0.1 nM G17 for 24 h (data 
not shown). After 8 h 10 nM G17, there was a significant 
decrease in the nuclear abundance and increase in the 
cytoplasmic abundance of p27 in a time-dependent manner 
(Figure 4F). 
The decreased p27 protein expression caused by 
10 nM G17 for 24 h was completely reversed by pre-
treatment of cells with Ro-32-0432 (1 µM), LY294002 
(20 µM), YM022 (100 nM) and netazepide (100 nM) 
and partially reversed by PD98059 (20 µM) (Figure 5A). 
AGSGR cells transfected with a chemically synthesised 
miR-222 mimic showed a dose dependent decrease in 
p27 mRNA and protein expression (Figure 5B and 5D); 
this was significant at miR-22 mimic concentrations 
> 50 nM. The chemically synthesised miR-222 inhibitor 
at concentrations > 500 nM also partially reversed the 
decrease in p27 mRNA and protein expression caused by 
10 nM G17 (Figure 5C and 5E). 
In 30 week old hypergastrinemic INS-GAS mice, 
p27 mRNA expression was also significantly decreased 
Figure 2: miR-222 expression was significantly increased in mucosal scrapings taken from the gastric corpus (A) 
and in the serum (B) of 30 week old hypergastrinemic INS-GAS mice relative to 30 week old FVB/N mice, with 
significant differences also being observed between 12 week and 30 week old INS-GAS mice in the serum (n = 10 per 
group). Statistical significance was determined using two-way ANOVA with Sidak post-hoc test and P < 0.05 was considered significant 
*P < 0.05, **P < 0.01 and ****P < 0.0001 between groups. In both gastric corpus biopsies (C, E) and serum samples (D, F) from patients 
with hypergastrinemia and type 1 gastric neuroendocrine tumors (n = 8), miR-222 expression was significantly higher at baseline compared 
with normogastrinemic healthy controls who had a normal stomach at endoscopy (n = 10). miR-222 expression decreased whilst patients 
were taking netazepide and returned to baseline after cessation of treatment, in short (12 weeks, C and D) and long (1 year, E and F) term 
studies. Statistical significance was determined using a Mann Whitney U test between healthy controls and baseline, and by Wilcoxon 
signed rank test with Bonferroni correction between treatment visits. P < 0.0125 was considered significant after correction, *P < 0.0125, 
**P < 0.001 and ***P < 0.0001.
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relative to age matched FVB/N wild-type mice and 
12 week old FVB/N wild-type mice (n = 10 per group). 
There were no significant differences  between 12 week 
old FVB/N wild-type and INS-GAS mice or 12 week 
and 30 week old INS-GAS mice (Figure 6). These data 
suggest that gastrin stimulates CCK2R activation leading 
to increased miR-222 expression which in turn decreases 
p27 mRNA and protein expression via the PKC and PI3K 
signalling pathways. 
The reduced p27 expression induced by gastrin 
increases migration and the extension of long 
processes in AGSGR cells
AGSGR cells were transfected with CDKN1B (p27) 
siRNA and Western blots confirmed that p27 protein 
expression was dose dependently decreased after 48 h 
transfection. The decreased p27 expression was significant 
following transfection with siRNA concentrations > 25 nM 
(Figure 7A). The decreased p27 protein expression 
induced by 25 nM p27 siRNA caused significant increases 
in cell migration (Figure 7B and 7D) and the extension of 
long processes in AGSGR cells (Figure 7C and 7E). 
DISCUSSION
In summary we have demonstrated that miR-222 
expression is increased in AGSGR cells following G17 
treatment and that the abundance of this miRNA is 
also increased in the gastric mucosa and serum of 
hypergastrinemic mice and humans. Increased gastrin-
induced miR-222 expression leads to increased migration 
Figure 3: Scratch wound assays were performed to assess cell migration (A) and scattering assays used to assess the 
expression of long processes (B) following G17 treatment of AGSGR cells. Chemically synthesised miR-222 mimics significantly 
increased migration (C) and the extension of long processes (D) with statistical significance determined using one way ANOVA with Tukey 
post-hoc test. Whereas miR-222 inhibitors significantly reduced the migration (E) and extension of long processes (F) that were stimulated 
by 10 nM G17 treatment of AGSGR cells, in a dose dependent manner and statistical significance was determined using two-way ANOVA 
with Sidak post-hoc test. P < 0.05 was considered significant, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
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and the extension of long processes in AGSGR cells, 
cellular events which are associated with gastric tumor 
development. miR-222 exerts these effects at least in part 
by decreasing p27 expression and causing this protein to 
be mislocalised in the cytoplasm (Figure 8).
There are few previous reports of the regulation of 
microRNAs by gastrin. However miR-449 expression 
was shown to be significantly downregulated in the 
antrum of gastrin knockout mice relative to wild-type 
counterparts [25]. The transcription factor E2F1 promotes 
miR-449 transcription which inhibits the oncogenic genes 
CDC25A and CDK6. Reduced expression of CDC25A and 
CDK6 causes dephosphorylation of the retinoblastoma 
protein (pRB), which arrests the cell cycle and reduces 
further E2F1 release [26, 27]. Dysregulation of the miR-
449/pRB-E2F1 regulatory loop therefore increases E2F1 
activity and promotes cell cycle progression and inhibits 
apoptosis in gastric cancer. miR-146a expression is also 
Figure 4: p27 mRNA expression significantly decreased dose (A) and time (B) dependently in AGSGR cells treated with 
gastrin. p27 protein expression dose (C) and time (D) dependently decreased following gastrin treatment of AGSGR cells. Fold-changes 
were maximal after 10 nM G17 for 24 h. Representative immunofluorescence images were taken after 24 h treatment with or without 
10 nM G17 (×400 magnification) (E). 10 nM G17 treatment of AGSGR cells (2–6 hrs) showed the shuttling of p27 with a significant 
increase in cytoplasmic mislocalisation of p27 after 8 h, in a time-dependent manner (F). Statistical significance determined using either 
one way ANOVA with Tukey post-hoc test or two-way ANOVA with Sidak post-hoc test and P < 0.05 was considered significant.*P < 0.05, 
***P < 0.001 and ****P < 0.0001.
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Figure 5: Western blot analysis indicated that LY294002 (20 μM), YM022 (100 nM), netazepide (100 nM) and Ro-32-
0432 (1 μM) all completely reversed while PD98089 (20 μM) partially reversed the reduction in p27 expression caused 
by 10 nM G17 treatment for 24 h. (A) A chemically synthesised miR-222 mimic significantly reduced p27 mRNA and protein 
expression (B, D) whereas a chemically synthesised miR-222 inhibitor partially reversed the reduced p27 mRNA and protein expression 
that was caused by 10 nM G17 treatment for 24 h (C, E) in AGSGR cells. Statistical significance was determined using one way ANOVA 
with Tukey post-hoc test or two-way ANOVA with Sidak post-hoc test and P < 0.05 was considered significant. *P < 0.05, **P < 0.001 
and ****P < 0.0001. 
Oncotarget45470www.impactjournals.com/oncotarget
up-regulated in the stomach of gastrin-knockout mice and 
also in 73% of tested gastric cancers. It targets CARD10 
and COPS8, resulting in reduced expression of NF-κB [28].
Several microRNAs have, however, been shown 
to be dysregulated in gastric adenocarcinoma and in the 
H. pylori infected stomach (reviewed in [29–31]). These 
miRNAs influence a number of cellular pathways that are 
involved in gastric carcinogenesis including apoptosis, 
proliferation and metastasis. Moreover certain miRNAs 
have also shown promise as biomarkers of both diagnosis 
and prognosis in gastric cancer [29–31].
Among the miRNAs dysregulated in gastric cancer 
is miR-222. miR-221 and miR-222 are encoded in tandem 
from a gene cluster located on chromosome Xp11.3 
[32]. Overexpression of miR-222 occurs in several other 
malignancies including breast, lung, papillary thyroid, 
prostate and glioblastoma [33–37]. In the GI tract, miR-222 
is upregulated in cancers of the esophagus, stomach, 
colon, liver and pancreas and shows decreased expression 
in cholangiocarcinoma and gastrointestinal stromal tumors 
(reviewed in [38]). miR-222 expression is increased in the 
plasma of patients with gastric cancer relative to patients 
with chronic active gastritis and healthy controls. Higher 
levels are associated with more advanced disease [39] and 
reduced 5 year survival [40]. miR-222 expression is also 
increased in gastric cancer tissue-derived mesenchymal 
stem cells [41] and in the stomachs of H. pylori infected 
individuals [42, 43].
miR-222 has several downstream mRNA targets 
including p27kip1, p57, PUMA, PTEN, Bim and MMP1 
(reviewed in [44]). Specifically in the stomach, increased 
miR-222 expression in H. pylori infected AGS cells post-
transcriptionally regulates RECK and promotes cancer-cell 
growth and invasion [43, 45]. miR-222 also targets the tumor 
suppressor PTEN in SGC7901 gastric cancer cells [46]. 
This negatively regulates the Akt pathway and promotes 
progression through the cell cycle via the inhibition of p27 
and p57 [47]. miR-222 overexpression is also associated 
with reduced expression of VGLL4 in human gastric cancer 
cell lines and tissues suggesting that miR-222 inhibits the 
translation of VGLL4 and promotes YAP-TEAD activation, 
which is sufficient to increase tumor proliferation, epithelial-
mesenchymal transition and invasion [45]. 
One of the best characterised downstream targets 
of miR-222 is p27kip1 (p27). miR-222 has been shown to 
bind to the 3′ end of the p27 locus [48]. Several studies 
have suggested that miR-222-induced inhibition of p27 
influences tumor development. There have until very 
recently been few data linking p27 expression in the 
stomach specifically to gastrin, but several investigators 
have previously studied the importance of p27 during H. 
pylori induced gastric carcinogenesis. H. pylori infection 
decreases the expression of the cell cycle inhibitor protein 
p27 at both transcriptional and post-translational levels. 
H. pylori modulates the G-protein coupled delta opioid 
receptor (DOR) which regulates the histone acetylation of 
Figure 6: p27 mRNA expression significantly decreased with age in the gastric corpus mucosa of 30 week old 
hypergastrinemic INS-GAS mice compared with 12 week and 30 week old FVB/N wild-type mice (n = 10 per group) (D). 
Statistical significance was determined using two-way ANOVA with Sidak post-hoc test and P < 0.05 was considered significant. *P < 0.05 
and **P < 0.001.
Oncotarget45471www.impactjournals.com/oncotarget
the p27 gene (CDKN1B) [49]. In addition cagA+ H. pylori 
strains decrease the transcription of p27 through activation 
of the PI3K/Akt pathway [50]. H. pylori infection also 
promotes the threonine/serine phosphorylation of p27 
allowing its accumulation in the cytoplasm [51]. This 
impairs the ubiquitination of p27 which accelerates its 
degradation via a proteasome-dependent pathway during 
cell cycle progression [52]. p27-null mice show increased 
susceptibility to H. pylori induced gastric preneoplastic 
pathology [53]. Patients with H. pylori-induced chronic 
gastritis also show decreased gastric expression of p27, 
which is reversed following eradication of the bacterium 
[54, 55]. Long-term exposure to H. pylori in animal [56] 
and cell culture [57] models has also been shown to 
promote an apoptosis-resistant phenotype associated 
with decreased p27 expression [58]. A very recent paper 
has also demonstrated reduced p27 expression in gastric 
carcinoid tumors arising in transgenic mice that was 
hypergastrinemic as a result of deletion of Men1 and 
somatostatin along with treatment with omeprazole [59]. 
This was associated with alterations in p27 
phosphorylation with increases in P-p27Thr187, P-p27Ser10 
Figure 7: Western blot analysis confirmed that p27 25 nM siRNA knockdown for 48 h resulted in decreased protein 
expression (A). p27 25 nM siRNA knockdown for 48 h significantly increased cell migration (B, D) and the extension of long processes 
(C, E) in AGSGR cells. Images were taken at ×200 magnification. Statistical significance was determined using one way ANOVA with Tukey 
post-hoc test and P < 0.05 was considered significant. ***P < 0.001 and ****P < 0.0001.
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Figure 8: A schematic diagram of the signalling pathways that are activated by gastrin-CCK2R binding. miR-222 
transcription is increased via the PKC and PI3K pathways and partially via the MAPK pathway. The pri(mary)-miR-222 transcript is 
cleaved by the RNAse II enzyme Drosha into a hairpin structure (pre-miR-222) which is transported from the nucleus to the cytoplasm 
via exportin-5. Pre-miR-222 is cleaved by a second RNase II enzyme, Dicer, into mature miR-222 which associates with RISC to target 
imperfect complementary mRNA sequences. Mature miR-222 inhibits the translation of p27 which increases cell migration and epithelial 
mesenchymal transition in AGSGR cells.
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and P-p27Kip1Thr198 being observed. Moreover this paper 
also reported loss of p27 expression in human type 1 
gastric neuroendocrine tumors associated with atrophic 
gastritis and showed similar alterations in p27 distribution 
(by immunocytofluorescence as well as subcellular 
fractionation) in the CCK2R expressing AGS-E cell line 
following gastrin treatment [59].
p27 has a number of well described functions 
that may influence tumor development (reviewed in 
[60]). When located in the nucleus it is predominantly a 
cell-cycle inhibitor. The AGSGR cells used in this study 
show an unusual response to gastrin stimulation with 
direct inhibition instead of the expected stimulation 
of proliferation [21]. Therefore we did not consider 
this cell line to be a good model in which to study the 
effects of gastrin-induced p27 suppression upon cell-
cycle progression. However when p27 is located in the 
cytoplasm it also regulates cell migration and invasion in a 
cell cycle independent manner [60]. Thr198 phosphorylation 
of p27 increases its cytoplasmic localisation, inhibits RhoA 
(Ras homolog gene family, member A) activation and 
increases cell motility [61]. Our observation of cytoplasmic 
mislocalisation of p27 following gastrin treatment is 
therefore consistent with the increase in migration and 
change in morphology that was observed in AGSGR cells 
following treatment with gastrin and a miR-222 mimic.
In conclusion, gastrin induced the expression of 
miR-222 in CCK2R bearing cells. Increased amounts 
of miR-222 were also detected in the gastric mucosa and 
sera of hypergastrinemic patients with type 1 gastric 
NETs. This miRNA therefore has potential utility as a 
biomarker of hypergastrinemia and of type 1 gastric NETs. 
Measurement of serum miR-222 abundance may also be 
useful for monitoring the response to treatment with CCK2R 
antagonists such as netazepide. Further work is however 
needed to investigate whether increased serum miR-222 
abundance is specific to patients with type 1 gastric NETs 
or whether it is also increased in patients who have other 
causes for hypergastrinemia such as long-term proton 
pump inhibitor use. Gastrin-induced miR-222 upregulation 
appears to be functionally important. Increased miR-222 
expression results in decreased abundance of p27 mRNA and 
protein and causes p27 mislocalisation into the cytoplasm. 
This mechanism appears to contribute to the increased 
migration and actin remodelling observed in AGSGR cells 
following G17 treatment (Figure 8). We speculate that 
similar mechanisms may also be important during the 
development of gastrin-related gastric tumors in vivo.
MATERIALS AND METHODS
Reagents
Ro-32-0432, PD-98059, LY-294002 were from 
Calbiochem (Nottingham, UK), YM022 was from Tocris 
Bioscience (Bristol, UK), netazepide (YF476) was 
from Trio Medicines Ltd (London, UK) and amidated 
G17 was from Bachem (St. Helens, UK). Human 
miR-222 (MS00007609), miR-376c (MS00004046), 
RNU62 (MS00033740) and CDKN1B (p27) primers 
(QT00998445) were from Qiagen (Sussex, UK). Human 
GAPDH primers were from Eurogentec (Southampton, 
UK) with the following primer sequences: forward 
CAGCAAGAGCACAAGAGGAA and reverse GTGGTG 
GGGACTGAGTGT. 
CDKN1B (p27) siRNA and scrambled control 
siRNA were from GE Dharmacon (Lafayette, USA) 
as a combination of 4 pooled siRNA sequences 
(SMARTpool: ON-TARGETplus™ human CDKN1B 
(p27) siRNA and SMARTpool: ON-TARGETplus™ 
Non-targeting Pool siRNA) for maximal gene 
silencing. The CDKN1B (p27) siRNA sequences 
were as follows: CAAACGUGCGAGUGUCUAA, 
GCAGCUUGCCCGAGUUCUA, ACGUAAACAG 
CUCGAAUUA and GCAAUGCGCAGGAAUAAGG. 
Scrambled control siRNA sequences were as follows: 
UGGUUUACAUGUCGACUAA, UGGUUUACAU 
GUUGUGUGA, UGGUUUACAUGUUUUCUGA and 
UGGUUUACAUGUUUUCCUA. DharmaFECT 1 
transfection reagent (GE Dharmacon, Lafayette, USA) was 
used for siRNA transfection in AGSGR cells. Chemically 
synthesised miR-222 mimic (MSY0000279), miR-222 
inhibitor (MIN0000279), miR-1 mimic positive control 
(MSY0000416) and miScript negative control (1027271) 
were all from Qiagen (Sussex, UK). All other routine 
supplies were from Sigma (Poole, UK) unless otherwise 
stated.
Cell lines
The AGS human gastric adenocarcinoma cell line 
and a transfectant stably expressing the CCK2 receptor 
(AGSGR) were used as previously described [21]. The 
parental AGS cells were originally obtained from ATCC 
and both AGS and AGSGR cell lines were confirmed to 
be mycoplasma-free. Cells were cultured in Ham’s F12 
medium supplemented with 10% fetal bovine serum 
(Gibco, Paisley, UK), 2 mM L-Glutamine and 1% 
combined antibiotics streptomycin and penicillin and 
maintained in a humidified atmosphere of 5% CO2/ 95% 
O2. All treatments were carried out using serum free media 
and drug pre-treatments were for 20 mins prior to gastrin 
treatment.
Animals
All in vivo experiments were carried out on INS-
GAS mice on the genetic FVB/N background under 
UK Home Office project licence numbers 40/3392 and 
70/8457, granted after ethical approval. Animals were 
housed in specific pathogen free facilities with access to 
food and water ad libitum at the University of Liverpool. 
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Gastric corpus mucosal scrapes were obtained after 
12 weeks and 30 weeks of age and immediately flash 
frozen in liquid nitrogen.
Human samples
Human serum and corpus biopsies were obtained 
from 8 patients enrolled on a phase-2 clinical trial of 
the CCK2R antagonist netazepide (YF476) in subjects 
with autoimmune atrophic gastritis, hypergastrinemia 
and multiple type 1 gastric neuroendocrine tumors 
(NETs), as previously described [4]. Control samples 
were obtained from 10 patients who had a normal upper 
GI endoscopy, normal gastric antral and corpus biopsy 
histology, no evidence of H. pylori infection by rapid 
urease test, histology or serology, were not taking proton 
pump inhibitors and who had fasting serum gastrin 
concentrations < 40 pM.
RNA isolation and reverse transcription
Small RNAs were isolated from cells and human 
biopsies using the miRNeasy Mini Kit and from serum 
using the miRNeasy Serum/Plasma kit (both from 
Qiagen, Sussex, UK). Mouse corpus mucosal scrapes 
were homogenised via bead beating and total RNA was 
extracted using the High Pure RNA Tissue kit (Roche, 
Sussex, UK). All extractions were performed according 
to the manufacturer’s supplementary protocols. Eluted 
RNA was reverse transcribed into cDNA using the 
miScript RT II Kit (Qiagen, Sussex, UK) according to 
the manufacturer’s procedures handbook and stored as 
undiluted cDNA at −20°C prior to real-time PCR.
MicroRNA PCR array
cDNA was prepared using the miScript SYBR 
Green PCR Kit (Qiagen, Sussex, UK) according to 
the manufacturer’s instructions. The mixture was then 
loaded into each well of the 96-well miScript miRNA 
PCR array plate (Qiagen, Sussex, UK) and run in a real-
time LightCycler 480 (Roche, Sussex, UK). Data were 
analysed using the ΔΔCT method of relative quantification 
and the miScript miRNA PCR array data analysis software 
(Qiagen, Sussex, UK). Normalisation was against the 
average threshold cycle of the entire plate minus Ct values 
> 35 (the maximum threshold value) and 4 control genes 
(2 × miRTC and 2 × PPC) that were separately used to 
assess reverse transcription and PCR performance. 
Primer assays
Mature miRNAs were assessed using primer assays 
for miR-222 with RNU62 for normalisation according to 
the miScript miRNA Primer Assay Handbook (Qiagen, 
Sussex, UK). Messenger RNA was assessed using primer 
assays for CDKN1B (p27) with GAPDH for normalisation 
according to the Quantitect Primer Assay Handbook 
(Qiagen, Sussex, UK) and run in a real-time LightCycler 
480 (Roche, Sussex, UK). Each sample was run in 
quadruplicate, which were analysed by the ΔΔCT method 
for relative quantification. 
Small interfering RNA (siRNA) transfections
AGSGR cells were transfected with SMARTpool: 
ON-TARGETplus™ human CDKN1B (p27) siRNA 
(L-003472-00-0005) or SMARTpool: ON-TARGETplus™ 
Non-targeting Pool siRNA (D-001810-10) (both from GE 
Dharmacon) for 48 h according to the manufacturer’s 
instructions and using DharmaFECT 1 transfection 
reagent. Cell culture medium was then changed to serum-
free medium when 10 nM G17 treatment was applied.
MicroRNA (miRNA) mimic and inhibitor 
transfections
AGSGR cells were transfected with either a 
chemically synthesised miR-222 mimic (MSY0000279) 
or inhibitor (MIN0000279), a miR-1 positive control 
(MSY0000416) or miScript negative control (1027271) for 
24–72 h according to the manufacturer’s instructions and 
with the use of HiPerfect transfection reagent (301704)
(all from Qiagen). Cell culture medium was then changed 
to serum-free medium when 10 nM G17 treatment was 
applied.
Western blot
Protein extracts were prepared and electrophoresed 
on 12% SDS-polyacrylamide gels, followed by 
transfer onto nitrocellulose membrane (mdi; membrane 
technologies INC, Ambala Cantonment, India). Membranes 
were subsequently blocked in 5% non-fat milk in PBS 
with 0.1% Tween-20, followed by incubation with 
the following primary antibodies: mouse monoclonal 
anti-p27 antibody (BD Biosciences, Oxford, UK) 
at a dilution of 1:5000 or mouse monoclonal anti-actin 
antibody (Neomarkers, Freemont, CA) at a dilution of 
1:2500. The secondary antibody was horseradish peroxidase 
(HRP)-conjugated rabbit anti-mouse immunoglobulins 
(Dako, Cambridge, UK) at a dilution of 1:2000. Membranes 
were developed using Supersignal (Pierce, Tattenhall, 
UK) and chemiluminescence was detected using a Bio-
Rad ChemiDoc XRS+(Bio-Rad, Hertfordshire, UK). 
Densitometry was performed using ImageLab software (V 
3.0) and results were normalised to actin.
Immunofluorescence
AGSGR cells were seeded onto 13 mm diameter 
coverslips (VWR international Ltd, Leicestershire, UK) in 
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24 well plates (Costar, High Wycombe, UK) at a density 
of 104/well and left to adhere for 24 h before treatment. 
After treatment, cells were washed and fixed with 4% 
paraformaldehyde. Cells were permeabilised with 0.2% 
PBT (0.03 g BSA, 10 ml PBS and 20 μl Triton-X 100) 
and blocked in 10% normal horse serum (Vectorlabs, 
Peterborough, UK) before overnight incubation with 
mouse monoclonal anti-CDKN1B (p27) primary antibody 
(diluted 1:500) at 4°C. To detect primary antibodies, 
the cells were incubated with horse anti-mouse FITC 
conjugated secondary antibody (Vectorlabs, Peterborough, 
UK) diluted 1:500 in 1% BSA in PBS for 1h, protected 
from light. Cells were mounted using Vectashield® media 
with DAPI (Vectorlabs, Peterborough, UK) onto glass 
slides for visualisation. Images were captured using an 
Olympus BX51 fluorescence microscope (Olympus, 
Sussex, UK) for at least 5 reference fields per treatment at 
400× magnification and analysed using ImageJ. Cells were 
scored as a percentage of total cells that contained nuclear 
only or nuclear and cytoplasmic p27 staining.
Cell migration assays
Monolayers of AGSGR cells were grown on 24 well 
plates in complete media before a cell-free region was 
created using a 2 μl pipette tip. Cells were washed twice in 
PBS followed by two washes in serum free media before 
treatment was applied. Whole cells that had migrated 
into the denuded region were counted and scratch wound 
width was measured using a graticule at 0 h and 8 h post 
treatment [22]. Representative images were taken at these 
times using a Zeiss Aviovert 25 microscope (Carl Zeiss 
Microscopy, New York, USA) at x200 magnification. 
Morphological assays
AGSGR cells were seeded in 24 well plates (10
4/well) 
in complete media and left to adhere for 24 h before 
treatment. After treatment, cells were fixed using 3:1 
methanol: acetic acid and stained with 0.3% crystal 
violet. The number of cells that presented long processes 
were counted as a percentage of total cells in 3 fields per 
treatment and representative images were taken using the 
Zeiss Aviovert 25 microscope (Carl Zeiss Microscopy, 
New York, USA) at ×200 magnification [23]. 
Statistics
Differences were assessed by either one-way 
ANOVA with  Tukey post-hoc test or two-way ANOVA 
with Sidak post-hoc test where appropriate and P < 0.05 
was considered significant. A Mann Whitney U test was 
used to assess statistical differences between independent 
healthy patient samples and baseline samples of patients 
taking netazepide. A Wilcoxon signed ranked test with 
Bonferroni correction was subsequently used to determine 
significant differences between repeated samples from the 
same patients as not all data were normally distributed and 
P < 0.0125 was considered significant after correction. 
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